ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by Columbus Venture Partners

ARTHEx Biotech has announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1...

Read more

ARTHEx Biotech Announces Closing of €42 M Series B Financing led by Columbus Venture Partners to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

by Columbus Venture Partners

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing...

Read more

El CDTI invierte junto a Invivo Ventures en Arthex Biotech, startup biotecnológica que pretende desarrollar nuevos tratamientos para la distrofia miotónica

by CDTI

El CDTI, a través de su programa Innvierte, conjuntamente con Invivo Ventures, han alcanzado un acuerdo con los socios de Arthex Biotech, S.L. para entrar en el capital de la startup. La aportación ...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

El CDTI Innovación invierte, junto con ...

by Moira Capital Partners

THE WISE SEEKER S.L.es una start-up fundada en 2018 por profesionales ...

Photos Stream